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18F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2
Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk
of Recurrence after Mastectomy
Original Article
Purpose
The purpose of this study is to assess the utility of positron emission tomography (PET) for
predicting recurrence among patients with T1-T2/N1 breast cancer who were treated with
mastectomy.
Materials and Methods
Of 712 consecutive patients with T1-T2/N1 breast cancer treated during 2003-2012, 109
had undergone preoperative 18F-fluorodeoxyglucose/PET and were included. Metabolic
(maximum standardized uptake value [SUVmax]), volumetric (metabolic tumor volume [MTV]),
and combined (total lesion glycolysis [TLG]) indices were measured. The resulting values
were analyzed and compared with clinical outcome.
Results
At the median follow-up of 46.7 months, the 3-year relapse-free survival (RFS) rate was
95.2%. SUVmax (area under curve, 0.824) was more useful than MTV or TLG as a means of
identifying patients at high risk for any recurrence. In multivariate analysis, SUVmax remained
an independent risk factor for RFS (p=0.006). Using the method of Contal and O’Quigley, 
a SUVmax threshold of 5.36 showed the best predictive performance. The PET-based high-
risk group (! 5.36 in either breast or nodes) had more T1c-T2, high-grade, hormone-receptor
negative, and invasive ductal carcinoma tumors than the low-risk group (< 5.36 in both
breast and nodes). The prognosis was much worse when high SUVmax (! 5.36) was detected
in nodes (p < 0.001). In the no-radiotherapy cohort, the PET-based high-risk group had 
increased risk of locoregional recurrence when compared to the low-risk group (p=0.037).
Conclusion
High SUVmax on preoperative PET showed association with elevated risk of locoregional 
recurrence and any recurrence. Pre-treatment PET may improve assessments of recurrence
risk and clarify indications for post-mastectomy radiotherapy in this subset of patients.
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Introduction
The results of meta-analyses by the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) showed that post-
mastectomy radiotherapy (PMRT) reduced the risks of recur-
rence and cancer death [1]. Updated studies confirmed ben-
efits of PMRT in patients with N1 disease, irrespective of the
use of systemic therapy and axillary dissection [2,3]. When
using modern treatment approaches, accurate identification
of high-risk patients for PMRT while sparing the remaining
patients from potentially unnecessary and costly therapy,
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and continuing to provide them with excellent local control
rates is imperative [4,5]. However, the indications for PMRT
are still determined on a case-by-case basis, and definitive
indications have varied significantly across institutions and
changed over time. Thus, the development of a practical
prognostic indicator for recurrence is required to optimize
the application of PMRT for this controversial situation.
18F-Fluorodeoxyglucose/positron emission tomography
(18F-FDG/PET), which detects the enhanced glycolysis of 
tumors, has emerged as a useful imaging tool in staging,
evaluation of treatment response, and predicting the prog-
nosis of breast cancer [6]. In Korea, 18F-FDG/PET staging is
reimbursed for patients who are newly diagnosed with
breast cancer; as a result, its use has increased for both locally
advanced and early-stage breast cancers. Here, we sought to
evaluate the potential utility of 18F-FDG/PET for predicting
prognosis in a group of T1-T2/N1 breast cancer patients who
underwent mastectomy, and we assessed the question of
whether this PET-based high-risk group was at increased
risk of locoregional recurrence after treatment without
PMRT, who might be potential candidates for adjuvant 
radiation therapy. 
Materials and Methods
1. Patients 
A total of 712 consecutive patients who underwent mas-
tectomy and were diagnosed with pathologic T1-T2/N1
breast cancer at a single institution between 2003 and 2012
were identified. Of these 712 patients, the 109 who under-
went preoperative 18F-FDG/PET scanning were included in
the current study. At our institution, 18F-FDG/PET staging
was first offered to patients with early breast cancer in 
November 2003. An increase in systemic staging with 
18F-FDG/PET was observed in our study cohort during the
study period (2003-2009: n=46/361, 14% vs. 2010-2012:
n=63/114, 55%).
2. Treatment
All patients underwent modified radical mastectomy. Sen-
tinel lymph node (SLN) sampling was performed in all 
patients, except those (19%) who had biopsy-confirmed or
suspicious axillary nodal metastasis on PET imaging. If the
frozen section of the SLN was positive, the patient under-
went completion of axillary dissection (median, 12 nodes;
range, 4 to 34 nodes). Although PMRT was delivered at the
physician’s discretion, it was generally performed for 
Table 1. Patient, tumor, and treatment characteristics
Characteristic No. (%) (n=109)
Age (yr)
< 45 29 (27)
! 45 80 (73)
Histology
IDC 100 (92)
Non-IDC 9 (8)
T stage
T1 61 (56)
T1a 2 (2)
T1b 15 (14)
T1c 44 (40)
T2 48 (44)
LVI
Negative 102 (94)
Positive 7 (6)
No. of positive lymph nodes
1 69 (63)
2 29 (27)
3 11 (10)
Percentage of positive lymph nodes
< 25 103 (94)
! 25 6 (6)
ECE
Negative 100 (92)
Positive 9 (8)
Histological grade
1 21 (20)
2 60 (57)
3 25 (24)
Estrogen receptor status
Negative 25 (23)
Positive 84 (77)
Progesterone receptor status
Negative 48 (44)
Positive 61 (56)
HER2 overexpression
Negative 73 (69)
Positive 33 (31)
Systemic chemotherapy and/or 105 (96)
hormone therapy
Chemotherapy    94 (86)
AC±T 75 (69)
CMF 14 (13)
Unspecified 5 (5)
Hormone therapy 58 (53)
Post-mastectomy radiotherapy
No 72 (66)
Yes 37 (34)
IDC, invasive ductal carcinoma; LVI, lymphovascular 
invasion; ECE, extracapsular extension; AC, adriamycin
cyclophosphamide; T, paclitaxel docetaxel; CMF, cyclop-
hosphamide methotrexate 5-fluorouracil.
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patients with high-risk features (mainly based on the number
of positive lymph nodes). Adjuvant systemic therapy was 
selected after discussion with the patient’s medical oncolo-
gist. 
3. 18F-FDG/PET
18F-FDG/PET scans were performed using a dedicated
PET/computed tomography (CT) scanner (Discovery STE,
GE Healthcare, Little Chalfont, UK, or Biograph TruePoint
40, Siemens Healthcare, Erlangen, Germany). The mean time
interval from PET scan to mastectomy was 10±9 days. The
detailed protocols for measurement of blood glucose concen-
tration, determination of injected 18F-FDG quantity, low-dose
and contrast enhanced CT and PET scans, and PET data 
reconstruction have all been described previously [7]. Semi-
quantitative and volumetric measurements of maximum
standardized uptake value (SUVmax), mean SUV (SUVmean),
metabolic tumor volume (MTV), and total lesion glycolysis
(TLG) of whole body tumors were performed with the PET-
edge tool that is available in MIMvista software (MIMvista
Corp., Cleveland, OH), according to the protocol of Liao et
Table 2. Comparisons of PET indices in whole body tumors according to clinicopathologic parameters (n=109)
Variable SUVmax p-value MTV (mL) p-value TLG p-value
Age (yr)
< 45 3.99±2.44 0.099 5.15±3.81 0.042 13.84±13.92 0.038 
! 45 5.09±3.24 7.77±6.46 22.54±28.90
Histology
IDC 5.04±3.07 < 0.001 7.22±5.75 0.409 21.19±26.52 0.196 
Non-IDC 2.01±1.08 5.49±8.32 9.47±16.79
T stage
T1 4.12±2.29 0.014 5.40±5.14 0.001 12.17±13.29 < 0.001
T2 5.65±3.70 9.19±6.33 30.46±33.71
LVI
Negative 4.75±3.10 0.570 7.01±6.00 0.671 19.90±26.39 0.551 
Positive 5.42±2.84 8.04±5.92 24.97±20.37
No. of positive LNs
1 4.43±2.59 0.101 6.22±5.23 0.051 15.84±17.40 0.020 
2, 3 5.43±3.71 8.54±6.90 27.79±35.37
Positive LNs (%)
< 25 4.82±3.10 0.695 7.17±5.98 0.507 20.34±26.25 0.852 
! 25 4.31±2.89 5.49±6.10 18.28±23.14
ECE
Negative 4.81±3.08 0.869 6.97±5.61 0.546 19.20±21.59 0.532 
Positive 4.63±3.25 8.23±9.52 31.57±56.55
Histological grade
1, 2 3.97±2.59 < 0.001 6.04±5.02 0.004 14.05±16.20 0.002 
3 7.73±2.85 10.93±7.40 42.04±38.88
Estrogen receptor status
Negative 6.66±4.03 0.008 9.50±6.19 0.020 33.72±31.19 0.014 
Positive 4.24±2.50 6.35±5.75 16.21±22.96
Progesterone receptor status
Negative 5.52±3.53 0.028 9.22±7.00 0.001 29.37±32.93 0.002 
Positive 4.22±2.55 5.39±4.38 13.03±15.74
HER2 overexpression
Negative 4.73±2.64 0.818 6.77±5.38 0.538 17.44±18.66 0.237 
Positive 4.90±3.98 7.63±7.10 25.64±37.16
PET, positron emission tomography; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG,
total lesion glycolysis; IDC, invasive ductal carcinoma; LVI, lymphovascular invasion; LN, lymph node; ECE, extracapsular
extension.
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al. [8]. After contouring the tumor using the PETedge tool,
volumes of interest (VOIs) were automatically produced by
spatial derivatives to locate the tumor surface. The estimated
VOIs were manually adjusted using a 2-D “ball” contouring
tool. In this study, SUVmax was the maximum SUVmax of all
tumors either in breast tissue or in the axillary area. TLG was
calculated as follows: TLG=SUVmean"MTV. MTV and TLG
were computed after summing the corresponding values of
all tumors. 18F-FDG/PET was administered at the clinical dis-
cretion of the treating physician during the study period.
4. Statistical analysis
The primary end-point of our study was relapse-free sur-
vival (RFS), defined as the length of time from the date of
mastectomy to any type of relapse. RFS was estimated using
the Kaplan-Meier method. Comparisons of PET parameters
according to clinical parameters or any recurrence (locore-
gional recurrence and distant metastasis as first site of fail-
ure) were performed using t tests. One-way analysis of
variance (ANOVA) with a post-hoc Bonferroni’s correction
was used for multiple comparisons. Receiver operating char-
acteristics (ROC) analyses were performed to determine
which parameter was most useful for predicting disease 
recurrence risk. Univariate and multivariate analyses of dis-
ease-free survival (DFS) were performed using Cox’s propor-
tional hazards regression method to assess whether the PET
parameter retained statistical significance after adjusting for
known clinicopathologic variables. Clinically relevant vari-
ables were selected, and multivariate analysis was performed
using backwards elimination. The method of Contal and
O’Quigley was used to determine the cut-off point for the
PET parameter, to allow objective dichotomization [9]. Using
this method, the optimal cut-off point is determined by set-
ting it to the point that maximizes the model likelihood. 
Because all possible cut-off points are assessed, an adjust-
ment is applied to the p-value to control for type I error.
Next, to identify the subgroup of patients who may benefit
from PMRT, a secondary analysis was performed, excluding
patients who underwent PMRT (no-PMRT cohort). The level
of statistical significance was set at 0.05. All statistical analy-
ses were performed using SPSS ver. 20.0 (IBM SPSS Statistics,
IBM Co., Armonk, NY) or SAS (SAS Institute Inc., Cary, NC). 
Results
1. Patient, tumor, and treatment characteristics
The median follow-up period was 46.7 months (range, 14
to 127 months). Data on patient, tumor, and treatment char-
acteristics are summarized in Table 1. The median age of 
patients was 49 years (range, 27 to 92 years). The mean tumor
size was 2.0±0.9 cm (range, 0.4 to 4.5 cm). SLN sampling was
performed in 87 patients (81%), with a median of 3 (range, 
1 to 7) identified. Axillary dissections were performed in all
patients with a median of 12 (range, 4 to 34) total nodes dis-
sected. Adjuvant systemic therapy was administered in most
patients (105 of 109, 96%) as follows: chemotherapy (n=94,
86%) and endocrine therapy (n=58, 54%). PMRT was deliv-
ered to 34% of the patients. 
2. Semiquantitative analysis of PET parameters
Most patients (97.2%) had 18F-FDG–avid tumors in the pri-
mary site, and 22 patients (20.2%) had 18F-FDG–avid tumors
in axillary nodes. For whole body tumors (WT), the average
SUVmax, MTV, and TLG was 4.79±3.07, 7.07±5.97 mL, and
20.22±26.0, respectively. For 18F-FDG–avid tumors in breast
tissue (n=106), the average SUVmax, MTV, and TLG was
4.75±3.01, 5.92±5.02 mL, and 17.49±23.48, respectively. For
18F-FDG–avid tumors in axillary nodes (n=22), the average
SUVmax, MTV, and TLG was 4.70±3.38, 4.09±4.14 mL, and
12.00±16.13, respectively. 
Significant correlations were observed among three 
parameters (TLGWT vs. MTVWT, Spearman’s rho=0.882;
Table 3. Comparisons of PET indices in breast, lymph node, and WT according to T classification (n=109)
T stage Breast Lymph node WT SUVmax
Non-avid SUVmax Non-avid SUVmax
T1a 0/2 (0) NA 2/2 (100) NA NA
T1b 1/15 (6.7) 1.84±0.39 13/15 (86.7) 3.00±2.80 3.55±2.03
T1c 0/44 (0) 4.80±1.97 35/44 (79.5) 3.64±2.15 5.59±2.00
T2 2/46 (4.2) 8.45±4.49 37/48 (77.1) 5.87±4.06 8.94±4.38
Values are presented as number (%) or mean±standard deviation. PET, positron emission tomography; WT, whole body 
tumors; SUVmax, maximum standardized uptake value; NA, not applicable. 
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TLGWT vs. SUVmax WT, rho=0.718; MTVWT vs. SUVmax WT,
rho=0.574; all p < 0.001). Differences in SUVmax WT, MTVWT,
and TLGWT according to clinicopathologic parameters are
shown in Table 2. A significantly higher mean SUVmax WT was
observed for invasive ductal carcinoma (IDC) tumors com-
pared with non-IDC tumors (p < 0.001). Significantly higher
mean values of SUVmax WT, MTVWT, and TLGWT were observed
in T2, high-grade (G3), estrogen receptor (ER)–negative, or
progesterone receptor (PR)–negative, tumors than in T1, non-
high grade (G1/2), ER+, or PR+ tumors, respectively (all 
p < 0.05). In addition, as T stage increased, SUVmax of breast,
axillary nodes, and WT were increased and more FDG-avid
tumors were found in axillary nodes (T1a, 0%; T1b, 13.3%;
T1c, 20.5%; T2, 22.9%) (Table 3).
3. Recurrence 
At the time of analysis, six patients (6%) had experienced
any recurrences, three presented with locoregional recur-
rence and three presented with distant metastasis. Six 
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(B).  
Jee Suk Chang, 18F-FDG/PET and N1 Breast Cancer 
VOLUME 48  NUMBER 2  APRIL  2016 513
patients (6%) died, either with (n=2) or without (n=4) disease
progression. The 3-year RFS and overall survival (OS) rates
were 95.2% (95% confidence interval [CI], 91.1% to 99.3%)
and 91.8% (95% CI, 84.7% to 98.9%), respectively. The rela-
tionship between SUV results and tumor recurrence was 
examined; patients with any recurrence had higher levels of
SUVmax WT, MTVWT, and TLGWT at baseline than those without
any recurrence (Fig. 1A). Similar levels of SUVmax WT, MTVWT,
and TLGWT were observed between patients who failed 
locoregionally or distally (all p=0.001; ANOVA with Bonfer-
roni correction) (Fig. 1B). 
4. Usefulness of PET for predicting recurrence
ROC curves were generated for SUVmax WT, MTVWT, and
TLGWT (Fig. 2). In the ROC analyses, the areas under the
curves (AUCs) were 0.824 (95% CI, 0.715 to 0.932) for SUVmax,
0.733 (95% CI, 0.574 to 0.892) for MTV, and 0.778 (95% CI,
0.629 to 0.928) for TLG. These results indicated that SUVmax WT
was the most useful index for predicting patients at high risk
of developing any recurrence. The relationship of SUVmax WT
with the time of any recurrence was also assessed after 
adjusting for all available clinicopathological variables. In
univariate analysis, increased SUVmax WT (considered as a con-
tinuous variable) showed significant association with poorer
RFS (p=0.001). The significance of this relationship with RFS
was retained in the stepwise multivariate regression analysis
(p=0.004) (Table 4).
The method of Contal and O’Quigley was also used to 
objectively determine a cut-off point for SUVmax WT [9]. 
According to this method, the best predicted clinical per-
formance was a threshold of 5.36, which provided a sensitiv-
ity, specificity, positive predictive value, and negative
predictive value of 100%, 71%, 17%, and 100%, respectively.
The patients were then divided into two groups (high- vs.
low-risk) according to this cut-off point, and the characteris-
tics of patients with SUVmax WT ! 5.36 were compared to those
Table 4. Stepwise univariate and multivariate analyses using Cox’s regression method for disease-free survival in 109 
patients
Variable Univariate analysis Multivariate analysis
a)
HR 95% CI p-value HR 95% CI p-value
Age (! 45 yr vs. < 45 yr) 0.63 0.12-3.48 0.597 0.14 0.01-2.24 0.165
T stage (T1 vs. T2) 0.46 0.08-2.55 0.373 NI -
No. of positive LNs (1 vs. 2, 3) 0.77 0.14-4.22 0.761 0.19 0.01-3.74 0.276
Histological grade (1, 2 vs. 3) 0.63 0.12-3.44 0.593 0.02 0.00-0.73 0.032
Estrogen receptor status (positive vs. negative) 0.16 0.03-0.86 0.033 0.04 0.00-0.60 0.020
Progesterone receptor status (positive vs. negative) 0.76 0.15-3.76 0.734 NI - -
HER2 overexpression (positive vs. negative) 1.19 0.22-6.51 0.844 NI - -
Post-mastectomy radiotherapy (yes vs. no) 0.39 0.05-3.41 0.396 0.06 0.00-2.58 0.141
18F-FDG–avidity in axillary nodes (avid vs. non-avid) 4.30 0.87-21.29 0.074 NI - -
SUVmax (as continuous) 1.43 1.15-1.78 0.001 1.77 1.19-2.62 0.004
HR, hazard ratio; CI, confidence interval; LN, lymph node; 18F-FDG, 18F-fluorodeoxyglucose; SUVmax, maximum standardized
uptake value. a)Variables were entered into the multivariate regression model in a stepwise method if p < 0.20 and were 
removed at any point if p-value was > 0.20.
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of patients with SUVmax < 5.36. PET-based high-risk patients
(SUVmax WT ! 5.36) had more T1c-T2 (vs. T1a-T1b), high-grade,
ER/PR negative, and IDC (vs. non-IDC) tumors than low-
risk patients (SUVmax WT < 5.36) (all p < 0.05). Three-year RFS
was 85.4% in the PET-based high-risk group compared with
100% in the low-risk group (p < 0.001) (Fig. 3A). The prog-
nosis was much worse when high SUVmax (! 5.36) was 
detected in axillary lymph nodes (p < 0.001) (Fig. 3B). 
5. Locoregional recurrence in the no-PMRT cohort
In the no-PMRT cohort (n=72), an increased risk of locore-
gional recurrence was observed for the PET-based high-
risk group, compared with the PET-based low-risk group 
(3-year locoregional recurrence-free survival, 92.9% vs. 100%; 
p=0.037) (Fig. 3C). However, age, T stage, number of positive
lymph nodes, histologic grade, ER/PR/HER2 status, 
18F-FDG–avidity in axillary nodes, and other factors did not
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show significant association with risk of locoregional recur-
rence.
Discussion
In this study, we have described the efficacy of PET for
identifying patients with T1-T2/N1 breast cancer with a high
risk of disease recurrence after mastectomy and standard sys-
temic therapy. We found an association of higher SUVmax WT
with both poorer RFS in the entire cohort and a higher risk
of locoregional recurrence in the no-PMRT cohort. The 
SUVmax cut-off value that best predicted prognosis was 5.36.
Compared with tumors in the PET-defined low-risk group,
tumors in the high-risk group were more likely to have the
following characteristics: T1c-T2 (vs. T1a-T1b) stage, high
grade, ER/PR negativity, and IDC (vs. non-IDC). In conjunc-
tion with conventional risk stratification that relies on mul-
tiple factors, preoperative 18F-FDG/PET information may
enable identification of high-risk groups with enhanced 
accuracy. We hypothesize that once these select groups are
identified, they may represent the population of T1-2/N1
breast cancer patients who might benefit from PMRT. 
Previous retrospective studies have investigated the use-
fulness of PET in breast cancer, with findings similar to ours
[10-14]. Osborne et al. [10] reported that ER– tumors had
higher 18F-FDG-uptake than ER+ tumors (median SUVmax, 8.5
vs. 4.0). A study by Mavi et al. [11] reported that ER status
alone (rather than PR or HER2 status) had an effect on FDG
uptake (F=9.126, p < 0.01). Baba et al. [12] reported correla-
tion of high SUVmax with larger tumor size, higher grade, and
triple-negative tumors, as well as poor prognosis (5-year
DFS: ! 4.16 [n=32], 80% vs. < 4.16 [n=28], 100%). Song et al.
[13] reported that nodal SUVmax was the only determinant of
DFS among well-known clinical variables in N1-3 patients
(n=65), similar to our finding that high SUVmax in lymph
nodes was associated with worse RFS than high SUVmax in
the primary tumor. Nakajima et al. [14] reported association
of MTV and TLG with tumor size, number of positive nodes,
nodal ratio, nuclear grade, ER status, and triple negative sta-
tus. Nakajima et al. [14] found that larger MTV was an inde-
pendent risk factor for locoregional recurrence-free survival
and DFS. In comparison with our cohort of patients, the 
cohort considered by Nakajima et al. [14] had different char-
acteristics, including a higher proportion of T2 disease (63%
vs. 44%), more biologically aggressive behavior (SUVmax,
MTV, and TLG; median 7.2, 31.7, and 73.4 vs. mean 4.8, 7.1,
20.2), and lesser use of chemotherapy (62.4% vs. 86%). These 
differences may have increased the importance of MTV in
the study by Nakajima et al. [14] as compared with our own.
However, both studies found that the AUC of SUVmax was
high (> 0.80), and the consistency of these findings should be
highlighted. 
Compared with other studies, our study had the following
strengths: (1) the cohort consisted of a homogenous group of
patients with pathologic T1-T2/N1 disease, who were
treated with mastectomy and current standard adjuvant
therapy. In addition, (2) we did not limit the investigation to
metabolic (SUVmax) values, but also assessed volumetric
(MTV) values and the combination of both indices (in the
form of TLG). The relationships between these indices, RFS,
and locoregional recurrence were then evaluated. Finally, 
(3) the analyses focused on an issue that is currently relevant
in clinical practice. 
From a cost-effectiveness perspective, it is not clear
whether PET should be offered to all patients with T1-T2/N1
disease, in order to identify those at high risk of recurrence,
and accordingly indicate PMRT. If our results are confirmed
in other series, cost-effectiveness will present another clinical
issue. Currently, National Comprehensive Cancer Network
(NCCN) experts recommend against the routine use of PET
in early breast cancer because of high false-negative rates in
small or low grade breast tumors, low sensitivity for detec-
tion of nodal metastasis, low prior probability of distant
metastasis, and (mainly) cost-ineffectiveness [15]. However,
recent studies (including studies with prospective designs)
have raised the possibility that PET may have a role in stage
II breast cancer [15-19]. The following studies reported rele-
vant results: Groves et al. [17] found that PET impacted can-
cer management in 16% of patients with stage II disease,
Groheux et al. [15] reported that PET modified staging in
5.5% of patients with stage IA disease and 13% of patients
with stage IB disease, and the Ontario Clinical Oncology
Group Study reported that PET could influence surgical care
by avoiding unnecessary SLN biopsies [16]. 
Our study has several limitations, including those that are
inherent to retrospective analyses. Because of the small num-
ber of events (recurrences), it was not possible to perform a
more complete statistical analysis. Longer follow-up is
needed to clarify the relationship between 18F-FDG uptake
and dormancy/late recurrence. Although the 5-year OS did
not differ significantly according to the use of PET in our 
cohort (n=712; 5-year OS rate, 93.1% with PET vs. 91% with-
out PET; p=0.412), it is possible that selection bias in our
study sample resulted in a better prognosis in the PET group,
affecting the results in terms of the cut-off value.
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Conclusion
In conclusion, we found that a high SUVmax (! 5.36) was 
associated with an increased risk of locoregional recurrence,
as well as any recurrence. Patients with high SUVmax in
lymph node involvement appeared to have a much worse
prognosis than those with high SUVmax in primary tumors.
However, these findings are purely hypothesis generating;
confirmatory studies with larger cohorts and longer follow-
up periods are necessary before PET-defined risk assessment
can be routinely adopted for early breast cancer. Efforts to
define the optimal cut-off values of PET parameters are also
necessary.
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